Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

One blood test to rule out heart attacks?

NCT ID NCT01334645

Diagnosis Sponsor: University Hospital, Clermont-Ferrand Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 06, 2026 · Last updated Aug 07, 2026 · Updated 1 time

Summary

This study is testing whether measuring a protein called copeptin in the blood, alongside the standard troponin test, can help doctors quickly rule out a heart attack in people arriving at the emergency room with chest pain. Participants with chest pain that started within the last 12 hours will have blood samples taken over several hours to measure copeptin, troponin, and other markers. The goal is to see if a normal copeptin and troponin result can safely exclude a heart attack without the need for prolonged monitoring and repeated blood tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Copeptin blood test
What this could lead to
If it works, this could lead to faster, simpler diagnosis of heart attacks, reducing the need for prolonged monitoring and repeated blood draws.
What could go wrong
This is a small, early-stage diagnostic study. The test may not prove accurate enough to replace current methods, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

134 people

The number who actually took part.

Start date

Mar 2011

Finished

Mar 2012

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Chest pain suggestive of Acute Coronary Syndrome * Chest pain with onset within the last 12 h * Patients older than 18 years Exclusion Criteria: * ST-Elevation Myocardial infarction * Legal incapacity * Sepsis * Hyponatremia \< 135 mmol/L * Shock * Lung neoplasms * life expectancy of less than 6 months * Refuse to consent

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chest pain are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome Chest Pain diabetes insipidus disease intermediate coronary syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chest pain

Contacts and locations

Locations

  • CHU Clermont-Ferrand

    Clermont-Ferrand, 63003, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.